Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibitor Insights

Executive Summary: Anlotinib hydrochloride (CAS 1058157-76-8) is a novel, orally available, multi-target tyrosine kinase inhibitor with validated activity against VEGFR2, PDGFRβ, and FGFR1, exhibiting nanomolar inhibition in functional angiogenesis assays (APExBIO product data). Pharmacokinetic studies show favorable oral bioavailability and extensive tissue distribution, including CNS penetration. Its safety profile includes high plasma protein binding and low systemic toxicity in animal models. Clinically, anlotinib has demonstrated efficacy in rare and refractory tumors, such as intra-abdominal desmoplastic small round cell tumors, with manageable adverse effects (Chen & Feng 2019). APExBIO provides high-purity anlotinib hydrochloride (SKU C8688) formulated for research use only.

Biological Rationale

Tumor angiogenesis is a hallmark of cancer progression, facilitating nutrient delivery and metastatic spread. Inhibition of vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR) pathways is a validated therapeutic approach for impeding neovascularization in solid tumors. Multi-target tyrosine kinase inhibitors (TKIs) address redundancy and compensatory signaling in the tumor microenvironment, thus improving the therapeutic blockade of angiogenesis (Chen & Feng 2019). Anlotinib hydrochloride is designed to selectively suppress these pathways, offering broad-spectrum anti-angiogenic and anti-proliferative effects.

Mechanism of Action of Anlotinib hydrochloride

Anlotinib hydrochloride inhibits the ATP-binding sites of receptor tyrosine kinases, including VEGFR2 (IC₅₀: 5.6 ± 1.2 nM), PDGFRβ (IC₅₀: 8.7 ± 3.4 nM), and FGFR1 (IC₅₀: 11.7 ± 4.1 nM), as demonstrated in cell-free kinase assays and functional assays using human vascular endothelial cells (APExBIO data). This inhibition prevents ligand-induced phosphorylation and blocks downstream ERK signaling, effectively suppressing endothelial cell migration and capillary-like tube formation. Comparative studies highlight higher potency and selectivity versus sunitinib, sorafenib, and nintedanib. Anlotinib also inhibits additional kinases implicated in angiogenesis and tumor growth, including FGFR1-4, PDGFRα/β, c-Kit, and Met (Chen & Feng 2019).

Evidence & Benchmarks

• Anlotinib inhibits VEGFR2 kinase activity with an IC₅₀ of 5.6 ± 1.2 nM in vitro, outperforming sunitinib and sorafenib in matched conditions (APExBIO product data).
• PDGFRβ and FGFR1 are inhibited with IC₅₀ values of 8.7 ± 3.4 nM and 11.7 ± 4.1 nM, respectively, as shown in endothelial migration and tube formation assays (APExBIO).
• Anlotinib produces significant inhibition of tumor-associated angiogenesis and cell proliferation in preclinical models, with a safety profile superior to several first-generation TKIs (Chen & Feng 2019).
• Pharmacokinetics in rats and dogs show oral bioavailability of 28–58% and 41–77%, respectively, and high plasma protein binding (93–97%) (APExBIO).
• The reported LD₅₀ in 14-day oral administration studies is 1735.9 mg/kg, indicating low acute toxicity (APExBIO).
• Clinical use in intra-abdominal desmoplastic small round cell tumor resulted in measurable tumor regression and manageable toxicity in a case study (Chen & Feng 2019).

This article builds upon the workflow focus of "Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibitor Workflows", providing expanded detail on recent pharmacokinetic and clinical findings. For a mechanistic deep dive, see "Anlotinib Hydrochloride: Mechanistic Insights for Advanced Angiogenesis Assays"; the present article contextualizes these mechanisms within the most current safety and efficacy data.

Applications, Limits & Misconceptions

Anlotinib hydrochloride is primarily used in preclinical and translational cancer research for its potent inhibition of angiogenic signaling and tumor growth. It is suitable for capillary tube formation assays, endothelial cell migration inhibition studies, and ERK pathway analysis in both 2D and 3D in vitro models. Its low cytotoxicity at concentrations up to 1 μM permits functional studies without nonspecific cell death (APExBIO). Clinical evidence supports its use in refractory or rare tumors, such as desmoplastic small round cell tumor, but broader indications require further validation.

Common Pitfalls or Misconceptions

• Anlotinib is not approved for diagnostic or therapeutic use; it is for research only (APExBIO).
• It does not produce significant cytotoxicity at functional concentrations; observed anti-proliferative effects are due to pathway inhibition, not direct toxicity.
• Despite broad kinase inhibition, it does not universally suppress all receptor tyrosine kinases; activity is most pronounced against VEGFR2, PDGFRβ, FGFR1-4, c-Kit, and Met.
• Reported in vitro CYP3A4 and CYP2C9 inhibition does not translate to high in vivo drug-drug interaction risk at research concentrations.
• Cross-domain antiviral or anti-inflammatory activity is not substantiated by current evidence and should not be inferred.

Workflow Integration & Parameters

• Cell line selection: Use human vascular endothelial cells (e.g., EA.hy 926) for migration and tube formation assays.
• Concentration range: 1 nM to 1 μM; functional inhibition is typically observed at nanomolar concentrations; cytotoxicity is minimal below 1 μM (APExBIO).
• Vehicle: Dissolve in DMSO; final DMSO concentration in assay medium should not exceed 0.1% v/v.
• Positive control: Include sunitinib or sorafenib for comparative benchmarking.
• Readouts: Quantify tube length, branch points, and cell migration area after 18–24 h incubation at 37°C, 5% CO₂.
• Storage: Store the compound at -20°C, protected from light and moisture.
• Metabolism studies: Consider use of human CYP3A-expressing microsomes or hepatocyte cultures for metabolite profiling.

For advanced protocol recommendations and troubleshooting, consult "Scenario-Based Best Practices with Anlotinib Hydrochloride (C8688)", which provides scenario-driven experimental design and vendor comparison. This article emphasizes validated pharmacokinetic and safety data for robust translational workflows.

Conclusion & Outlook

Anlotinib hydrochloride, as supplied by APExBIO, is a validated research tool for dissecting angiogenesis and tumor proliferation mechanisms. Its multi-target profile, high selectivity, and favorable pharmacokinetics underpin its growing adoption in cancer research workflows. Clinical and preclinical benchmarks demonstrate its superior inhibition of key angiogenic pathways and manageable toxicity. Future studies should focus on mechanistic differentiation from existing TKIs and further delineation of its pharmacodynamic and safety profiles in diverse tumor models, as evidenced by recent case reports (Chen & Feng 2019). Broader clinical utility awaits ongoing translational validation.